LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today that it will be presenting a business update at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York City on November 9, 2017.
DermTech will be making the presentation at 3:30 PM ET during the conference at the Westin New York Grand Central Hotel, 212 East 42nd Street, New York, where interested investors may sign up for one-on-one meetings with the company’s senior management.
“We are very excited to be attending Canaccord Genuity’s Medical Technologies and Diagnostics Forum to provide an overview of DermTech’s gene expression platform technology and business model, especially given Canaccord’s leadership position in healthcare technology investment banking and research,” said Steven Kemper, CPA, DermTech’s Chief Financial Officer.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
About Canaccord Genuity
With operations in Canada, the US, the UK & Europe, the Middle East and Asia-Pacific, and the ability to list companies on 10 exchanges, Canaccord Genuity is a leading independent global investment bank focused on growth companies.